Flydubai FZ1073 Co-Pilot Accused of Terror Attack 
Ripple Locks 700 Million XRP Back in Escrow After October Release 
Chainalysis AI Traces $387M Bitget Hack in Under 10 Minutes 
California AG Subpoenas OpenAI Over AI Cybersecurity Incidents 
Volvo Cars Drops Full-Year Outlook as China, US Sales Weaken 
Trump Praises Boeing 737 Max After Flydubai Crash Attempt 
Robinhood Stock Nears $114 as Jobs Data Boosts Risk Appetite 
SoftBank Shares Fall After $10 Billion OpenAI Investment 
Goldman Sachs Names CATL, Zenergy Top China Battery Picks 
Bank of America Sees EUR/USD at 1.15 by Year-End 
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin 
Zcash Awards $8 Million in Grants After Orchard Bug Crisis 
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats 
Circle Urges EU to Revise MiCA Stablecoin Rules 
AAVE, PUMP, WLD and SKY Rally as Crypto Market Slips 
Nike Stock Slides as Revenue Miss Clouds Turnaround 
Citi Raises Bitcoin Price Target to $113,000 on ETF Optimism 
Add as a preferred source on Google
PARSIPPANY, N.J., May 10, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Bank of America Merrill Lynch 2017 Healthcare Conference at 8:00 AM PT on Wednesday, May 17, 2017 in Las Vegas.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
